Authors:
Michele Russo, Mario Montanino Oliva, Maurizio Nordio, Giuseppina Porcaro, Vittorio Unfer
Abstract
Background: In the field of polycystic ovary syndrome (PCOS), metformin and myo-inositol are frequently employed to treat the endocrine-metabolic aspects of the condition. Accordingly, myo-inositol is sometimes considered as a nutraceutical alternative for metformin. Both compounds have undergone repurposing efforts to identify new applications; however, the mechanisms of both these compounds differ considerably, as does their potential in conditions outside of PCOS.
Objectives: This paper discusses contrasts both molecules in terms of mechanism, possible adverse effects, and novel indications, with an aim of detangling the unique properties of each molecule.
Methods: A narrative review was conducted independently by the authors using the search platforms PubMed, Google Scholar, and Web of Science between August and November 2024.
Conclusions and outlook: Myo-inositol has a more acceptable safety profile than metformin, which is known to be associated with gastrointestinal adverse effects and, in rare cases, lactic acidosis. Myo-inositol is a naturally present molecule in physiological conditions, which underlines its importance in a variety of biological functions, as opposed to the strict pharmacological action of metformin. Both myo-inositol and metformin have been investigated in several pathological fields, particularly in gynecology where they may improve pregnancy outcomes and fertility care. The safety profile of these molecules seems quite different since data, even if incomplete, sustain high tolerance of myo-inositol, while the safety of metformin use during pregnancy is still controversial. However, further study is required to fully understand the potential of each of these molecules, specifically within the fields of mental health and oncology.
